IP Library Granted Patent US 7,785,841
Granted Patent B2
US 7,785,841 · App. 11/012,787 · Granted Aug 31, 2010

Methods for the early diagnosis of ovarian cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,841
App. No.
11/012,787
Granted
Aug 31, 2010
Kind
B2
Abstract

The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically, the present invention relates to expression of PUMP-1 protease (matrix metalloprotease 7). The detected proteases are themselves specifically over-expressed in certain cancers, and their presence may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.

Claims (9)

1. A method for detecting ovarian cancer in a biological sample, comprising the steps of:

(a) isolating mRNA from said sample;

(b) performing quantitative PCR amplification on complementary DNA obtained from said mRNA using anti sense primers consisting of SEQ ID NO: 16 and SEQ ID NO: 17 to determine presence of a 250 basepair amplification product, wherein said amplification product hybridizes with a 1.1 kb mRNA isolated from ovarian carcinoma; and

(c) comparing amount of said 250 basepair amplification product from the sample with the corresponding amount of corresponding product obtained from a normal sample from normal tissues, wherein an increased amount of the 250 basepair amplification product in the sample compared to the normal sample from normal tissues is indicative of the presence of ovarian cancer.

2. The method of claim 1 , further comprising the step of:

comparing said 250 basepair amplification product to reference information, wherein said comparison provides a diagnosis of said ovarian cancer.

3. The method of claim 1 , further comprising the step of:

comparing said 250 basepair amplification product to reference information, wherein said comparison determines a treatment of said ovarian cancer.

4. The method of claim 1 , wherein said biological sample and said normal sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, tumor tissue biopsy and circulating tumor cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 044037/0496 →